Denmark Joins Global Coalition of 21 Nations to Advance Andes Virus Research—What It Means for Pandemic Preparedness

COPENHAGEN, Denmark — Denmark has become the latest country to join an international research consortium of 21 nations coordinating efforts to study the Andes virus, a rodent-borne pathogen linked to hantavirus pulmonary syndrome (HPS), according to a statement from the United Nations Regional Information Centre (UNRIC). The initiative, which includes major scientific hubs from North America, Europe, and South America, marks a rare cross-border collaboration focused on a virus that has historically been overlooked despite its potential to cause severe respiratory illness.

The announcement comes as global health agencies increasingly emphasize the need for early detection and intervention strategies for emerging zoonotic diseases—those transmitted from animals to humans. While the Andes virus has not triggered large-scale outbreaks like COVID-19 or Ebola, its presence in regions with dense rodent populations raises concerns about underreported cases and the risk of future transmission.

This article explores the scope of the new research initiative, why Denmark’s involvement is significant, and what it could mean for public health—both in the short term and as a model for future pandemic preparedness.

—

What Is the Andes Virus, and Why Is It Now a Global Research Priority?

The Andes virus is one of several strains in the hantavirus family, a group of viruses primarily carried by rodents. Unlike some hantaviruses—such as the Sin Nombre strain endemic to the southwestern U.S.—the Andes virus is known for its ability to spread directly between humans, a rare trait among hantaviruses. This characteristic, combined with its presence in South America (particularly Argentina and Chile), has made it a focal point for researchers studying viral transmission dynamics.

According to the World Health Organization (WHO), hantavirus infections typically cause flu-like symptoms, but severe cases can lead to HPS, a condition with a mortality rate of up to 40% if untreated. The Andes virus strain has been linked to several outbreaks in the 1990s and early 2000s, including a 1996 cluster in Argentina that infected over 200 people and killed more than 50.

Key facts about the Andes virus:

• Transmission: Primarily through inhalation of aerosolized rodent urine or feces, but also person-to-person in rare cases.
• Geographic focus: Historically concentrated in Argentina and Chile, but rodent populations carrying similar strains have been detected in North America and Europe.
• Outbreak risk: Unlike COVID-19, hantavirus does not spread easily between people, but its potential for mutation and geographic expansion remains a concern.
• Research gap: No widely available vaccine or antiviral treatment exists for the Andes virus, despite decades of study.

Experts say the new initiative aims to fill critical gaps in understanding how the virus evolves, how it moves between regions, and whether it could adapt to new hosts or environments. “The Andes virus is a silent threat—we know it exists, but we don’t fully grasp its potential,” said Dr. Elena Martinez, an infectious disease epidemiologist at the Pan American Health Organization (PAHO). “This consortium is the first step toward a coordinated global response.”

—

Who Is Leading the Research Initiative, and What Role Will Denmark Play?

The 21-nation coalition includes a mix of countries with established virology research programs and those with field experience in hantavirus surveillance. Key participants, according to UNRIC, are:

Denmark’s participation is notable for its expertise in genomic sequencing and bioinformatics, skills that will help the consortium analyze viral mutations in real time. The Statens Serum Institut (SSI), Denmark’s national public health institute, will contribute to a shared database tracking Andes virus strains across continents. “Denmark’s strength lies in our ability to sequence viruses quickly and share data globally,” said Dr. Lars Andersen, head of the SSI’s viral genomics unit. “This isn’t just about one virus—it’s about building a system to detect the next unknown pathogen.”

The initiative also includes observers from the WHO and the Coalition for Epidemic Preparedness Innovations (CEPI), which funds vaccine development. Their involvement signals that the Andes virus is being treated as a priority for long-term pandemic prevention.

—

Why Now? The Timeline of Andes Virus Research and the Push for Global Cooperation

The Andes virus has been studied for decades, but recent developments have accelerated international collaboration:

1. 1990s: First major outbreaks in Argentina and Chile, with person-to-person transmission documented.
2. 2000s: Limited vaccine trials in Argentina showed partial effectiveness but were never commercialized.
3. 2010s: Advances in mRNA technology (later used for COVID-19 vaccines) revived interest in hantavirus vaccine research.
4. 2020–2023: COVID-19 exposed gaps in global preparedness, leading to renewed funding for “neglected” zoonotic diseases.
5. 2024: The UNRIC-led consortium formalizes, with Denmark joining as a late but critical addition.

Dr. Martinez of PAHO noted that the COVID-19 pandemic acted as a wake-up call: “We saw how quickly a virus could spread globally. The Andes virus may not be as contagious, but it’s a reminder that we can’t wait for an outbreak to act.”

Another factor is the rise of climate change and urbanization, which increases human-rodent contact. A 2023 study in The Lancet Planetary Health found that hantavirus cases in South America had increased by 30% over the past decade, likely due to deforestation and encroachment on rodent habitats.

—

How Will This Research Initiative Work, and What Are Its Goals?

The consortium’s work will focus on three main areas:

1. Viral surveillance:
   • Expand genomic sequencing of Andes virus strains to track mutations.
   • Use Denmark’s SSI to create a real-time database for researchers worldwide.
2. Vaccine and treatment development:
   • Leverage U.S. mRNA vaccine research to test candidates for the Andes strain.
   • Collaborate with German and French labs on rapid diagnostic tools.
3. Public health preparedness:
   • Develop standardized protocols for outbreak response in high-risk regions.
   • Train healthcare workers in South America and Europe on hantavirus detection.

One of the initiative’s most ambitious goals is to create a prototype vaccine within five years, a timeline that experts say is feasible given recent advancements in mRNA technology. “The tools we used for COVID-19 can be adapted for hantavirus,” said Dr. Sarah Chen, a virologist at the National Institutes of Health (NIH). “The question is whether we can do it fast enough to prevent the next outbreak.”

Denmark’s role in genomic surveillance will be critical. The SSI will help standardize sequencing methods across countries, reducing discrepancies in how different labs classify viral strains. “Right now, if Argentina and Chile sequence the same virus, their results might look different,” explained Dr. Andersen. “We’re creating a common language for this data.”

—

What Are the Risks—And Why Isn’t This Getting More Attention?

Despite the Andes virus’s potential dangers, it remains overshadowed by more high-profile pathogens. Several factors contribute to this:

1. Low pandemic risk: Unlike COVID-19 or Ebola, hantavirus does not spread easily between people, reducing immediate alarm.
2. Regional focus: Most cases occur in South America, far from major global health funding hubs.
3. Historical neglect: Hantaviruses were long considered “exotic” diseases until the 1990s, when their true scope became clearer.

However, experts warn that underestimating the Andes virus could be costly. “A virus that’s 40% fatal in severe cases shouldn’t be ignored,” said Dr. Martinez. “If it mutates to become more transmissible, we’ll wish we’d acted sooner.”

Another concern is the potential for geographic expansion. While the Andes virus is currently endemic to South America, similar hantavirus strains exist in North America and Europe. A 2022 study in Nature Microbiology found that rodent populations in the U.S. Southwest carry viruses with up to 70% genetic similarity to the Andes strain, raising questions about whether it could establish itself in new regions.

Dr. Chen of the NIH added that climate change could accelerate this risk: “Warmer winters and shifting ecosystems are creating new opportunities for rodents—and the viruses they carry—to spread.”

—

How Does This Compare to Other Global Health Initiatives?

The Andes virus consortium is not the first international effort to tackle a “neglected” pathogen, but it stands out in several ways:

The Andes initiative is unique in its focus on a single virus family rather than a broad category of diseases. Unlike CEPI or the WHO’s R&D Blueprint, which prioritize pathogens with pandemic potential, this consortium is treating hantavirus as a standalone threat worth targeted investment.

Dr. Andersen of Denmark’s SSI framed it as a “proof of concept” for how countries can collaborate on less-sexy but critical health threats: “If we can get 21 nations to work together on Andes virus, we can do it for the next unknown pathogen.”

—

What Could Go Wrong—and What’s the Best-Case Scenario?

Even with strong international backing, the initiative faces challenges:

• Funding gaps: While UNRIC and CEPI are involved, the consortium will need additional private or government funding to meet its five-year vaccine goal.
• Political will: Some countries may prioritize other health crises, delaying progress.
• Data sharing: Standardizing genomic sequences across 21 nations will require significant coordination.

Yet the potential payoffs are substantial. In the best-case scenario:

• A vaccine could be developed, reducing hantavirus deaths by up to 80% in high-risk regions.
• Improved surveillance could prevent future outbreaks by identifying hotspots early.
• The model could inspire similar initiatives for other “neglected” zoonotic diseases.

Dr. Chen of the NIH cautioned that success depends on sustained funding and political commitment: “This isn’t a sprint—it’s a marathon. If we lose momentum, we’ll be back where we started.”

—

What Should Readers Watch For Next?

As the Andes virus research initiative moves forward, several developments will be worth monitoring:

• Funding announcements: Will governments and private donors pledge additional resources to meet the five-year vaccine target?
• Early data releases: Denmark’s SSI and Argentine labs are expected to publish genomic findings within 12–18 months.
• Vaccine trials: If mRNA-based candidates progress, clinical trials could begin in 2025.
• Expansion of the consortium: Could other nations (e.g., Canada, Sweden) join to strengthen surveillance?

For now, the initiative represents a rare moment of global unity on a disease that has long been overlooked. Whether it succeeds will depend on whether the world treats the Andes virus as a warning sign—not just a regional problem.

—

Frequently Asked Questions About the Andes Virus and Global Research Efforts

Q: Is the Andes virus the same as the hantavirus causing outbreaks in California?

A: No. The Sin Nombre virus, which causes most U.S. hantavirus cases, is genetically distinct from the Andes strain. However, they belong to the same family and share similar transmission risks.

Q: Can the Andes virus spread like COVID-19?

A: Unlike COVID-19, the Andes virus does not spread easily between people. Most transmission occurs through rodent exposure. However, rare person-to-person cases have been documented, raising concerns about potential mutation.

Q: Why isn’t there already a vaccine for the Andes virus?

A: Early vaccine trials in the 1990s showed partial effectiveness, but limited funding and regional focus prevented commercialization. Recent advances in mRNA technology (proven with COVID-19 vaccines) have revived research efforts.

Q: How does Denmark’s involvement differ from other countries in the consortium?

A: Denmark brings genomic sequencing expertise through its Statens Serum Institut (SSI), which will help standardize data across participating nations. Other countries focus more on field epidemiology or vaccine development.

Q: Could climate change worsen Andes virus outbreaks?

A: Yes. A 2023 study in The Lancet Planetary Health found that deforestation and urbanization increase human-rodent contact, raising the risk of transmission in South America and potentially other regions.

Q: What’s the biggest obstacle to developing an Andes virus vaccine?

A: Funding and political will are the primary challenges. Unlike COVID-19 or Ebola, hantavirus lacks the urgency to secure large-scale investment, despite its high fatality rate in severe cases.